Long-Term Data Show Reduction in Failures for Prostate Cancer Patients Using Hypofractionation

Background: Hypofractionated radiation for prostate cancer is now well accepted, but earlier studies have longer follow-up. The phase 3, prospective, randomized controlled trial from MD Anderson was undertaken to test the efficacy and safety of conventionally fractionated intensity-modulated radiation therapy (CIMRT) to 75.6 Gy in 1.8 Gy fractions delivered over 8.4 weeks versus 72.0 Gy in 2.4 Gy fractions (hypofractionated intensity-modulated radiation [HIMRT]) delivered over 6 weeks. Objective: To present long-term data with a median follow-up of 13 years of a randomized trial of mildly hypofractionated radiation treatment for localized prostate cancer. Design: Long-term update of the phase III trial from MD Anderson. Participants: Patients with T1b to T3b localized prostate cancer, prostate-specific antigen (PSA) level of <20 ng/mL, Gleason score of <10, and no evidence of nodal disease. Methods: Patients were randomized 1:1 between CIMRT to 75.6 Gy in 1.8 Gy fractions deliv more...